AstraZeneca commits $2 billion and shares costs for drug-combination trials. Possible research gains are not yet proven, so the story gives no clear change to its outlook.
The collaboration gives AstraZeneca a chance to test cancer-drug combinations. The trials have not reported results, and the company must invest $2 billion and share trial costs. Since the story reports no sales or proven benefit, the opportunity does not clearly outweigh the spending.
Summit receives $2 billion from newly issued shares, giving it funding for drug development after warning it might have to cut research. The planned trials still have no reported results.
Follow AstraZeneca Plc (AZN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for AZN